The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Today's health news includes understanding Plan B's efficacy for people with higher BMIs, disparities in infant mortality, ...

Big Data, Real World, Multi-State Study Finds RSV Vaccine Highly Effective in Protecting Older Adults Against Severe Disease, Hospitalization and Death Oct. 17, 2024 — This multi-state study is ...

the mRNA vaccines from Pfizer and Moderna — aren’t effective. Get top local stories in Southern California delivered to you ...

COVID-19 vaccination coverage has progressed unevenly throughout the world. Moreover, 1.01 and 1.43 doses for each person are ...

The CDC notes that PPSV23 is 60 to 70% effective at protecting people from serious disease caused by the 23 types of pneumococcal bacteria that the vaccine covers. PCV15, PCV20, and PCV21 are ...

Let's consider two examples: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these biotechs are ...

LILLE, France, Nov. 12, 2024 /PRNewswire/ -- Today Vaxinano, a biotech company headquartered in Lille (France) announced an ...

Request To Download Free Sample of This Strategic Report @ The publisher has been closely monitoring the various markets in Saudi Arabia Respiratory Disease Vaccine Market. This report provides a ...

New preclinical data demonstrates that CMV antigens identified with Evaxion's AI-Immunology platform trigger targeted immune responses Results also showcase the successful design of a proprietary pref ...